Validation of Preoperative Neoadjuvant Bevacizumab Therapy for Newly Diagnosed Glioblastoma via Comparative Analyses with Propensity Score Matching
Preoperative neoBev did not improve survival compared with standard chemoradiotherapy. However, it was associated with improved functional status, and exploratory imaging findings suggested associations between early radiographic response and outcome. NeoBev should not be used routinely but may have a contextual role in selected patients with perioperative challenges.
Authors
- Akihiko Teshigawara (ORCID: https://orcid.org/0000-0002-4219-4638)
- Kyoichi Tomoto (ORCID: https://orcid.org/0000-0002-7500-3850)
- H. Sasaki
- Toshihide Tanaka (ORCID: https://orcid.org/0000-0002-6474-6317)
- Jun Takei (ORCID: https://orcid.org/0000-0003-3879-9252)
- Yuzuru Hasegawa (ORCID: https://orcid.org/0000-0001-9252-4191)
- Ryota Tamura
- Yukina Morimoto
- Yasuharu Akasaki
- Yuichi Murayama
- Yohei Yamamoto
- Keisuke Miyake
Institutions
- Jikei University School of Medicine (JP)
- Kagawa University (JP)
- Keio University (JP)
- Tokyo Dental College Ichikawa General Hospital (JP)
- Jikei University Kashiwa hospital (JP)
Publication Details
- Journal
- Cancers
- Published
- 2026-02-01
- DOI
- https://doi.org/10.3390/cancers18030488
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00